Resumption of treatment with penicillamine after proteinuria.

Abstract

Penicillamine has been successfully reintroduced and continued for a minimum of 13 months in 5 patients who developed proteinuria during the first course of the drug. The daily maintenance dose during the second course was 150--250 mg taken midway between 2 meals. Proteinuria did not recur; no significant excretion of fibrin degradation products occurred; complement, urea, creatinine, and serum albumin remained within normal limits. Urine microscopy showed no abnormality.

• Authors: H Hill, A Hill, A M Davison
• Journal: Annals of the rheumatic diseases (Ann Rheum Dis) Vol. 38 Issue 3 Pg. 229-31 (Jun 1979) ISSN: 0003-4967 [Print] England
• PMID: 485579 (Publication Type: Journal Article)

Chemical References

• Penicillamine

Topics

• Arthritis, Rheumatoid (drug therapy)
• Drug Administration Schedule
• Female
• Humans
• Penicillamine (administration & dosage, adverse effects, therapeutic use)
• Proteinuria (chemically induced)